162 related articles for article (PubMed ID: 24201752)
1. Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects.
Ferreira AK; Santana-Lemos BA; Rego EM; Filho OM; Chierice GO; Maria DA
Br J Cancer; 2013 Nov; 109(11):2819-28. PubMed ID: 24201752
[TBL] [Abstract][Full Text] [Related]
2. Reactive oxygen species production triggers green tea-induced anti-leukaemic effects on acute promyelocytic leukaemia model.
Torello CO; Shiraishi RN; Della Via FI; Castro TCL; Longhini AL; Santos I; Bombeiro AL; Silva CLA; Queiroz MLS; Rego EM; Saad STO
Cancer Lett; 2018 Feb; 414():116-126. PubMed ID: 29129782
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic and anti-metastatic activity of synthetic phosphoethanolamine.
Ferreira AK; Freitas VM; Levy D; Ruiz JL; Bydlowski SP; Rici RE; Filho OM; Chierice GO; Maria DA
PLoS One; 2013; 8(3):e57937. PubMed ID: 23516420
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a retinoic acid-resistant human acute promyelocytic leukaemia (APL) model in human granulocyte-macrophage colony-stimulating factor (hGM-CSF) transgenic severe combined immunodeficiency (SCID) mice.
Fukuchi Y; Kizaki M; Kinjo K; Awaya N; Muto A; Ito M; Kawai Y; Umezawa A; Hata J; Ueyama Y; Ikeda Y
Br J Cancer; 1998 Oct; 78(7):878-84. PubMed ID: 9764578
[TBL] [Abstract][Full Text] [Related]
5. Synthetic phosphoethanolamine a precursor of membrane phospholipids reduce tumor growth in mice bearing melanoma B16-F10 and in vitro induce apoptosis and arrest in G2/M phase.
Ferreira AK; Meneguelo R; Marques FL; Radin A; Filho OM; Neto SC; Chierice GO; Maria DA
Biomed Pharmacother; 2012 Oct; 66(7):541-8. PubMed ID: 22902646
[TBL] [Abstract][Full Text] [Related]
6. A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
Muto A; Kizaki M; Kawamura C; Matsushita H; Fukuchi Y; Umezawa A; Yamada T; Hata J; Hozumi N; Yamato K; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2001 Aug; 15(8):1176-84. PubMed ID: 11480559
[TBL] [Abstract][Full Text] [Related]
7. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
[TBL] [Abstract][Full Text] [Related]
8. Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway.
de Figueiredo-Pontes LL; Assis PA; Santana-Lemos BA; Jácomo RH; Lima AS; Garcia AB; Thomé CH; Araújo AG; Panepucci RA; Zago MA; Nagler A; Falcão RP; Rego EM
PLoS One; 2011; 6(10):e26713. PubMed ID: 22053203
[TBL] [Abstract][Full Text] [Related]
9. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
Sohal J; Phan VT; Chan PV; Davis EM; Patel B; Kelly LM; Abrams TJ; O'Farrell AM; Gilliland DG; Le Beau MM; Kogan SC
Blood; 2003 Apr; 101(8):3188-97. PubMed ID: 12515727
[TBL] [Abstract][Full Text] [Related]
10. ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype.
Lucena-Araujo AR; Coelho-Silva JL; Pereira-Martins DA; Thomé C; Scheucher PS; Lange AP; Paiva HH; Hemmelgarn BT; Morais-Sobral MC; Azevedo EA; Franca-Neto PL; Franca RF; Silva CL; Krause A; Rego EM
Oncotarget; 2017 Jan; 8(5):8475-8483. PubMed ID: 28035072
[TBL] [Abstract][Full Text] [Related]
11. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
12. ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia.
Tong Q; You H; Chen X; Wang K; Sun W; Pei Y; Zhao X; Yuan M; Zhu H; Luo Z; Zhang Y
Nucleic Acids Res; 2018 Apr; 46(7):3284-3297. PubMed ID: 29554366
[TBL] [Abstract][Full Text] [Related]
13. Asynchronous expression of myeloid antigens in leukemic cells in a PML/RARalpha transgenic mouse model.
Santana BA; Pintão MC; Abreu e Lima RS; Scheucher PS; Santos GA; Garcia AB; Falcão RP; Rego EM
Braz J Med Biol Res; 2006 May; 39(5):615-20. PubMed ID: 16648899
[TBL] [Abstract][Full Text] [Related]
14. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia.
Turhan AG; Lemoine FM; Debert C; Bonnet ML; Baillou C; Picard F; Macintyre EA; Varet B
Blood; 1995 Apr; 85(8):2154-61. PubMed ID: 7536493
[TBL] [Abstract][Full Text] [Related]
15. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
[TBL] [Abstract][Full Text] [Related]
16. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
[TBL] [Abstract][Full Text] [Related]
17. Transcription therapy for acute promyelocytic leukaemia.
Douer D
Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia.
Grimwade D; Solomon E
Curr Top Microbiol Immunol; 1997; 220():81-112. PubMed ID: 9103677
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features.
Kizaki M; Matsushita H; Takayama N; Muto A; Ueno H; Awaya N; Kawai Y; Asou H; Kamada N; Ikeda Y
Blood; 1996 Sep; 88(5):1824-33. PubMed ID: 8781440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
